Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2023 06:54 ET | Source: Emergen Research

Chemiluminescence Immunoassay Analyzers Market Size Worth USD 9.7 Billion in 2032 | Emergen Research

Vancouver, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The global Chemiluminescence Immunoassay (CLIA) analyzers market size was USD 5.42 Billion in 2022 and is expected to register rapid revenue CAGR of 6.0%...
June 09, 2023 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics to Highlight Broad Pipeline at ENDO 2023

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the...
January 05, 2022 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
October 25, 2021 16:01 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
September 27, 2021 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting

- Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company...
June 16, 2021 08:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
May 06, 2021 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics...
November 16, 2020 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
November 13, 2020 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
September 04, 2020 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...

Next Page keyboard_arrow_right